Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference
Prescient will present the preclinical data on its next-generation cell therapy platforms at the ISCT conference held in Paris later this month.
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy (ISCT) in France later this month.
Prescient researchers will showcase new preclinical data on the company’s next-generation immune receptor platform OmniCAR and its cell therapy enhancement platform CellPryme.
Both abstracts will also be published in the next issue of the ISCT’s official journal Cytotherapy.
The ISCT is focused on pre-clinical and translational aspects of cell and gene-based therapeutic developments and aims to advance scientific research into innovative treatments for patients.
The annual conference brings together clinicians, regulators, researchers and industry partners with a shared vision to translate cell and gene technologies into safe and effective therapies.
It attracts more than 2700 experts from 60 countries each year.
Honoured to showcase
Prescient managing director Steven Yatomi-Clarke said the company was honoured to be presenting in front of ISCT delegates.
“To have two abstracts accepted by this prestigious conference is testament to the quality and novelty of our science, and also exemplifies how the OmniCAR and CellPryme platforms are positioned at the forefront of cell therapy utility and innovation,” he said.
Senior vice president of scientific affairs Dr Rebecca Lim said the meeting would give Prescient an opportunity to talk about developments in it oncology portfolio.
“We have made significant progress with the development of the OmniCAR and CellPryme platforms, which have the potential to advance the utility and utilisation of cell therapies,” she said.
“The ISCT meeting is a wonderful opportunity to showcase data to an expert cell therapy audience of researchers, clinicians and pharmaceutical industry delegates.”
Board appointment
Earlier this week, Prescient announced the appointment of Dr Ellen Feigal as a US-based independent and non-executive director.
Dr Feigal is currently partner and head of biologics at global life sciences advisory firm NDA Partners, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology.
She is also adjunct faculty at the Sandra Day O’Connor College of Law at Arizona State University, where she teaches medical research ethics and law.
Dr Feigal was formerly senior vice president (research and development) with the California Institute of Regenerative Medicine; executive medical director (global development) at US biotech company Amgen Inc; vice president (clinical sciences) at the Translational Genomics Research Institute; and director of the cancer treatment and diagnostics division at the US National Cancer Institute.
She serves as a board member for biotechnology company Xencor Inc and a director of cancer immunotherapy company NextCure.
Right mix of skills
Prescient chairman Steve Engle said Dr Feigal’s appointment ensures the board has the right mix of skills, diversity and independence.
“Ellen is an accomplished industry leader with a strong track record in the commercialisation of new cell-based treatments in the US and globally,” he said.
“Her deep operational understanding of cancer therapy regulatory pathways, manufacturing and markets will be valuable as Prescient approaches a clinical inflexion point for PTX-100 and progresses OmniCAR and CellPryme.”